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Paravalvular Leak After
Transcatheter Aortic Valve Replacement
The New Achilles’ Heel? A Comprehensive Review of the Literature
Philippe Généreux, MD,*†‡ Stuart J. Head, MSC,§ Rebecca Hahn, MD,*† Benoit Daneault, MD,*†
Susheel Kodali, MD,*† Mathew R. Williams, MD,*† Nicolas M. van Mieghem, MD,
Maria C. Alu, MM,* Patrick W. Serruys, MD, PHD, A. Pieter Kappetein, MD, PHD,§
Martin B. Leon, MD*†
New York, New York; Montréal, Québec, Canada; and Rotterdam, the Netherlands
Paravalvular leak (PVL) is a frequent complication of transcatheter aortic valve replacement (TAVR) and is seen
at a much higher rate after TAVR than after conventional surgical aortic valve replacement. Recent reports indi-
cating that PVL may be correlated with increased late mortality have raised concerns. However, the heterogene-
ity of methods for assessing and quantifying PVL, and lack of consistency in the timing of such assessments, is
a hindrance to understanding its true prevalence, severity, and effect. This literature review is an effort to consol-
idate current knowledge in this area to better understand the prevalence, progression, and impact of post-TAVR
PVL and to help direct future efforts regarding the assessment, prevention, and treatment of this troublesome
complication. (J Am Coll Cardiol 2013;61:1125–36) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.1039Transcatheter aortic valve replacement (TAVR) has become
the treatment of choice for inoperable patients with severe
aortic stenosis (1) and is comparable to surgical aortic valve
replacement (SAVR) for patients at high risk (2). However,
paravalvular leak (PVL) is more frequently seen after TAVR
than after SAVR, and its potential association with mortal-
ity has raised concerns (3–6). Moreover, recent reports have
suggested that PVL could negatively impact mid- and
long-term prognosis following TAVR (7,8). Although con-
cerning, the lack of standardized quantitative and qualitative
methods to assess and categorize PVL and the heterogene-
ity in the timing of post-procedural assessment of PVL
warrant caution in interpretation of these data. Therefore,
we sought to perform a systematic review of the current
literature to better define the rate, progression over time,
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accepted August 21, 2012.predictors, and consequences of PVL after TAVR. Further-
more, recommendations for measuring PVL are provided to
improve consistency throughout the literature.
Rate of PVL
Multiple studies have reported the frequency and severity of
PVL after TAVR (9). There is, however, significant heter-
ogeneity that is caused by differences in: 1) imaging modal-
ities (transthoracic echocardiography, transesophageal echo-
cardiography, angiography); 2) timing of assessment
(immediately after implantation, before discharge, at 30
days); 3) transcatheter heart valve (THV) system; 4) grading
scale; and 5) adjudication of events. When PVL was
evaluated before hospital discharge and without central core
laboratory analysis, its absence was reported in 6% to 59% of
patients, whereas moderate or severe PVL was seen in 0% to
24% (1–5,10–16) (Table 1).
Thus far, only the PARTNER (Placement of Aortic
Transcatheter Valve) trial has used a central echocardiogra-
phy core laboratory to evaluate PVL (1,2). PVL was graded
in accordance with the American Society of Echocardiog-
raphy recommendations for native valves (17) because there
were no recommendations for prosthetic valve assessment
at the start of the trial. In addition, because of the
inevitable eccentric nature of the jet and the frequent
“spray” of the jet contour in the outflow tract, the color
Doppler in the available parasternal short-axis view(s)
was weighted in a subjective fashion more heavily than
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integrated assessment. The fol-
lowing definition was applied:
no PVL (no regurgitant color
flow), trace (pinpoint jet in
atrioventricular [AV] short-axis
view), mild (jet arc length 10%
of the AV annulus short-axis view
circumference), moderate (jet arc
length 10% to 30% of the AV
annulus short-axis view circumfer-
ence), and severe (jet arc length
30% of the AV annulus short-
axis view circumference). In the
PARTNER trial, trace/mild PVL
as found in 66% of patients and moderate/severe in
2% (1,2).
Thus far, no prospective direct comparison of the rate of
VL after TAVR has been published between the 2 most
requently used THV systems (balloon-expandable THV,
dwards Lifesciences, Irvine, California; self-expandable
oreValve THV, Medtronic, Minneapolis, Minnesota).
owever, moderate to severe post-procedural PVL seems to
e slightly higher with the CoreValve (9% to 21%) (4–6,18–20)
han the Edwards (6% to 13.9%) (1–3,5,18,21,22) device.
ecent 1-year data presented from the FRANCE 2 (French
ortic National CoreValve and Edwards 2) Registry seemed to
onfirm this finding—the use of self-expandable prosthesis was
dentified as one of the major determinants of significant PVL
fter TAVR. At patient discharge, self-expandable prosthesis
as associated with a moderate to severe PVL rate of 19.8%,
ompared with 12.2% for balloon-expandable prosthesis
p value not available) (23).
rogression Over Time
ne of the initial concerns about PVL was potential
orsening during extended follow-up. Because a large
ercentage of patients are discharged with trace or mild
VL, worsening of PVL could have important conse-
uences on the volume load imposed on the left ventricle
LV), ultimately resulting in significant heart failure. In
ddition, if many cases progress to clinically significant
eakage, hemolysis requiring repeated transfusions or reop-
ration may further complicate the course of patients.
Despite the lack of “common language” among previous
eports in assessment of PVL severity, several studies have
eported comparable findings with respect to time trends of
VL severity. Webb et al. (24) reported the evolution of
VL over time in a cohort of 168 patients and found
hat PVL was generally mild and remained stable between
0-day and 1-year follow-ups, a result that has been
onfirmed by other studies (Table 2). A recent report by
ssia et al. (16) showed that rates of mild (53%) and
oderate (15%) post-procedural PVL had been reduced to
Abbreviations
and Acronyms
AR  aortic regurgitation
AV  atrioventricular
LV  left ventricle/
ventricular
PVL  paravalvular leak
SAVR  surgical aortic
valve replacement
TAVR  transcatheter
aortic valve replacement
THV  transcatheter heart
valve7% and 10%, respectively, at a follow-up of 3 years. Somettrition of the “sickest” patients might have been due to
atients with worsening PVL dying, but there were no cases
f worsening from mild to moderate/severe regurgitation in
ndividual patient progression of PVL.
Data from the PARTNER trial suggested, however, that
VL at 2 years had increased by 1 grade in 22.4% of
atients, whereas it remained unchanged in 46.2% and
mproved by 1 grade in 31.5% of patients (Fig. 1) (8). So
ar, no studies have explored the mechanisms behind im-
rovement or worsening of PVL in individual patients, and
easurement methods may explain, at least in part, these
hanges.
mpact on Clinical Outcomes
fter SAVR, moderate to severe residual aortic regurgita-
ion (AR) occurs infrequently in approximately 4% of
atients (25). A recent study showed that AR after SAVR
as an independent predictor of long-term mortality with a
azard ratio of 1.7 (95% CI: 1.2 to 2.3). The TAVR
ommunity has focused extensively on the effect of AR on
urvival because its prevalence is much higher after TAVR
han after SAVR (8). A number of studies have identified
R 2 to be an independent predictor of short- and
ong-term mortality (Table 3) (3). Furthermore, patients
ith AR 2 were 10 times more likely to be nonre-
ponders to therapy at 6 months’ follow-up; nonresponsive-
ess was defined as either death or New York Heart
ssociation classification 2.
Few studies have devoted analyses specifically to PVL.
his is not surprising because the low post-operative rate of
VL in surgical series makes statistical analysis not mean-
ngful. However, even in TAVR after which post-
rocedural AR is largely paravalvular, there have been only
few large registries and randomized trials focused on PVL.
ata on 663 patients from the Italian registry found that
VL grade 2 was not associated with early 30-day
mortality, but multivariate analysis did find a hazard ratio of
3.79 for patients with PVL 2 for late mortality beyond
30 days (6). More disturbingly, although it was generally
believed that only moderate or severe regurgitation would
impact long-term outcomes (26), the recently published
2-year results from the PARTNER trial showed that even
mild PVL was associated with significant mortality (Fig. 2)
(8). Multivariable analyses did not identify AR or PVL as
independent predictors of mortality in this trial, but, inter-
estingly, there is a trend toward improved survival in
patients undergoing TAVR compared with SAVR if PVL
was negligible (70% vs. 65%).
Importantly, based on the current literature, the direct
causal relationship between PVL and mortality (vs. PVL
being a marker for other factors) still needs to be deter-
mined. Careful analyses of baseline patient characteristics,
the repercussion of all degrees of PVL on LV geometry and
remodeling, and the determination of the precise cause of
death (cardiovascular vs. noncardiovascular) are needed to
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this point, any previous observations linking PVL (espe-
cially mild) with mortality should be considered hypothesis
generating.
Predictors of PVL
Significant PVL most commonly results from: 1) incom-
plete prosthesis apposition to the native annulus due to
patterns or extent of calcification (11,27–30) or annular
eccentricity (26); 2) undersizing of the device (10,31,32);
and/or 3) malpositioning of the valve (33). These observa-
tions seem to be true for both balloon-expandable and
self-expandable THVs.
Valve sizing has been shown to be one of the strongest
predictors of PVL. A low cover index reflecting a lower
degree of oversizing of the prosthesis based on transthoracic
echocardiography annulus measurement predicts significant
PVL (10). More recently, studies have evaluated the use of
multidetector computed tomography (MDCT) for THV
sizing, and MDCT showed good predictability and reduced
rates of significant PVL (34–37). Furthermore, larger and
eccentric annuli were identified as predictors of PVL in
multiple studies and most likely reflect inadequate sizing of
the THV (3,15,26). A smaller aortic valve area was found to
predict PVL in one study, but this was likely because the
smaller area indicates a greater degree of calcification (3).
The extent of calcification and asymmetrical distribution, as
well as the location of calcium on the aortic wall, valve
commissure, or THV landing zone, as a predictor for PVL
has been confirmed in several studies (11,26,29,37,38).
In studies specifically evaluating the CoreValve (Medtronic), a
lower depth of implantation and a greater angle between the
aorta and LV outflow tract were found to predict PVL
(14,15).
Assessment of Paravalvular Regurgitation
Angiographic and hemodynamic assessment. Aortic root
angiography is an established tool for qualitative and semi-
quantitative assessment of AR (39). It is readily available
during the TAVR procedure and can be quickly and safely
executed to provide essential information and initiate ad-
junctive maneuvers if needed in case of significant (para)
valvular AR. Typically, Sellers criteria are applied to grade
AR (40): 1) grade 1 or mild AR corresponds to a small
amount of contrast entering the LV during diastole without
filling the entire cavity and clearing with each cardiac cycle;
2) grade 2 or moderate AR corresponds to contrast filling of
the entire LV in diastole but with less density compared
with contrast opacification of the ascending aorta; 3) grade
3 or moderate to severe AR corresponds to contrast filling of
the entire LV in diastole equal in density to the contrast
opacification of the ascending aorta; and 4) grade 4 or severe
AR corresponds to contrast filling of the entire LV in
diastole on the first beat with greater density compared with
the contrast opacification of the ascending aorta. During thecontrast injection, no material may cross the aortic valve
leaflets (e.g., guidewires, catheters) because incomplete valve
closure may artificially be generated, thus resulting in AR.
Particularly with self-expanding systems, it is important to
wait some time (empirically 10 min) after deployment of the
bioprosthesis to allow the system to expand to its maximum.
The downside of qualitative aortography AR assessment is
that it relies on subjective interpretation of unidimensional
images; therefore, interobserver and intraobserver variability
can be an issue and additional contrast volume required.
Moreover, it is difficult to determine the contribution of
PVL and central AR.
Classic findings of acute AR (acute drop in the aortic
diastolic pressure with or without elevated LV end-diastolic
pressure [LVEDP]) may be seen after TAVR and may be
suggestive of moderate to severe AR. However, these
findings must be interpreted with caution because the
concomitant use of sedatives, vasopressors, inotropes, and
intravenous fluids all impact hemodynamics, and the pres-
ence of material through the aortic valve (e.g., wire) may
interfere temporarily with the THV function. Recently, the
AR index, the ratio of the end-diastolic gradient across the
aortic valve bioprosthesis to systolic blood pressure ([ADP 
LVEDP]/ASP; ADP-aortic diastolic pressure, ASP-aortic
systolic pressure), was described (41). An AR index 25
was associated with 1-year mortality. Although this associ-
ation is interesting, more data and validation are needed to
establish the role of this new index in the therapeutic
decision process after TAVR.
Echocardiographic assessment. Although the native valve
regurgitation quantitative grading scheme has been advo-
cated for the evaluation of prosthetic valve regurgitation
(42), there are limited data to support the use of these
parameters following TAVR. The majority of semiquanti-
tative parameters for assessing AR apply to central regurgi-
tant jets, which are more uniform, making semiquantitative
grading schemes more reliable.
Unlike central jets, paravalvular regurgitant jets are com-
monly eccentric with crescentic, irregular orifices. Because
these jets occur between the annulus and sewing ring, jet
areas and lengths may not represent the same severity of
regurgitation compared with central jets and these param-
eters cannot be used to reliably assess regurgitant severity.
Although guidelines suggest using the circumferential ex-
tent of the regurgitant jet as a semiquantitative measure of
severity (42), this parameter has not been validated against any
quantitative parameters of regurgitation. Even if we accept the
limited validation of this scheme for surgical prostheses, the
anatomy and physiology of THVs are different than that of
surgical valves. In the balloon-expandable valve, paravalvular
regurgitation should be assessed just below the skirt; for central
jets, the regurgitation should be assessed at the coaptation
point of the leaflets. In addition, there is no scheme that
specifically addresses the unusual regurgitation that accompa-
nies the THV. The intact calcified cusps and annulus signifi-
Selected Publications Reporting AR After TAVRTable 1 Selected Publications Reporting AR After TAVR
First Author, Year (Ref. #) n Approach Prosthesis Imaging Modality Severity Gradation Adjunctive Techniques AR Post-TAVR
Predictors of AR by
Multivariable
Analysis
Detaint, 2009 (10) 74 TF  46 (62%)
TA  28 (38%)
ES Echocardiogram (TEE)
Site reported (blinded
echocardiographist)
0  absent
1  trace/mild
2  mild/moderate
3  moderate/severe
4  severe
Post-dilation  5/74
Valve-in-valve  2/74
Early post-TAVR (TEE)
0  5 (7.0%)
1  53 (72.0%)
2  12 (16.0%)
3  4 (5.0%)
4  0 (0%)
2/4 AR
● Low cover index
● Operator’s
experience
Abdel-Wahab, 2011 (3) 690 TF  644
TA  26
SC  22
TAo  5
ES  110 (16%)
MCV  580 (84%)
Angiogram
Site reported
0  absent
1  trace/mild
2  mild/moderate
3  moderate/severe
4  severe
— Early post-TAVR (angiogram)
0  191 (27.7%)
1  380 (55.1%)
2  103 (14.9%)
3  14 (2.0%)
4  2 (0.3%)
2/4 AR
● AVA baseline
● Annulus baseline
● Cardiogenic shock
● Renal failure
● Male
Sherif, 2010 (14) 50 TF MCV Angiogram
Echocardiogram
Site reported
1  trivial/mild
2  moderate
3  moderate/severe
4  severe
— Early post-TAVR (angiogram)
0  3 (6.0%)
1  27 (54.0%)
2  13 (26.0%)
3  7 (14.0%)
4  0 (0%)
Early post-TAVR (TTE)
0  9 (18.0%)
1  24 (48.0%)
2  13 (26.0%)
3  4 (8%)
4  0 (0%)
2/4 AR
● Increase angle of
LVOT and
ascending aorta
● Depth of device in
relation to
noncoronary cups
John, 2010 (78) 100 TF  97 (97%)
SC  3 (3%)
MCV Angiogram
Echocardiogram
0
1
2
3
4
Post-dilation  34/100
Snare technique  4/100
Valve-in-valve  3/100
Early post-TAVR (angiogram)
0  35 (35.4%)
1  28 (28.3%)
2  19 (19.2%)
3  8 (0.8%)
4  0 (0%)
Early after adjunctive
technique (angiogram)
0 38 (38.4%)
1  49 (49.5%)
2  11 (11.1%)
3  1 (0.1%)
4  0 (0%)
AgS and DLZ-CS
showed
significant
correlation with
grade of PVL
after initial MCV
deployment
Takagi, 2011 (15) 79 TF  62 (78.5%)
SC  17
(21.5%)
MCV Angiogram
Echocardiogram
Site reported
0  absent
1  mild
2  moderate
3–4  severe
Post-dilation  21/79
Snare technique  1/79
Valve-in-valve  2/79
Final result (angiogram)
0  21 (26.6%)
1  42 (53.2%)
2  13 (16.5%)
3  3 (3.8%)
4  0 (0%)
2/4 AR
● Larger annulus
diameter
● Low implantation
● Peripheral vascular
disease
Continued on the next page
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March 19, 2013:1125–36 Paravalvular Leak After TAVRcantly influence the location and shape of paravalvular jets;
typically, these jets appear smaller and more irregular at the
level of the intact/calcified cusps and larger just apical to the
THV stent.
Quantitative assessment of total AR, or advanced imag-
ing techniques for assessing paravalvular regurgitant orifices,
may be a more accurate way of assessing severity and thus a
more accurate assessment of risk. Quantitative Doppler uses
comparative flow measurements across a regurgitant valve
and a nonregurgitant valve to calculate regurgitant volume
or fraction (17). The effective regurgitant orifice area is then
calculated by dividing the regurgitant volume by the velocity
time integral of the regurgitant jet continuous wave spectral
profile. Alternatively, the LV stroke volume calculated by
2-dimensional (2D) biplane Simpson method of discs (43) can
be used in place of total (regurgitant plus forward) stroke
volume; however, systematic underestimation of ventricular
volumes has been reported for this method. Although this
quantitative assessment has been largely validated in the
literature (44–51), has shown reproducibility, and is endorsed
by scientific authorities (17,52), it should be acknowledged that
this assessment is based on 4 parameters, any one of which may
be determined with significant inaccuracy.
Three-dimensional (3D) echocardiography can overcome
the limitations of 2D and standard Doppler measurements
for quantifying regurgitation (43). Pitfalls of 2D LV imag-
ing, including foreshortening, malrotation, and angulation,
can be overcome by 3D imaging. However, limitations of
3D imaging (lower line density and low volume rates) may
reduce the utility of this method for assessing total stroke
volume. Color Doppler 3D volumes can be useful for the
identification and localization of regurgitation jets, as well as
planimetry of the vena contracta area (53,54). This imaging
modality may be particularly useful for post-TAVR assess-
ment of PVL (55,56).
With the increased use of multimodality imaging capable
of 3D reconstruction of the aortic root (36,57–62), there
has been intense interest in the shape of the annulus and
appropriate sizing of the transcatheter heart valve to reduce
PVL. The oval shape of the annulus has been well documented
(36,60,61,63–65), and a single sagittal plane measurement is
significantly smaller than the coronary plane measurement.
Algorithms using 3D imaging tools have been suggested to
improve annular sizing and reduce PVL (34,35).
Recently, the Valve Academic Research Consortium
(VARC) published the VARC II definitions and suggested the
use of TAVR-specific criteria for the assessment of AR and/or
PVL after TAVR (Table 4) (66). Figures 2 and 3 illustrate
chocardiographic assessment of PVL after TAVR. Figure 4
llustrates a case using 3D echocardiography assessment of PVL.
reatment for Significant PVL
mproved positioning of the TAVR could require advanced
maging techniques for angiographic planning; having thebest coplanar view will ensure accurate fluoroscopic local-Co T
F T G M
A
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Paravalvular Leak After TAVR March 19, 2013:1125–36Progression of Aortic and/or Paravalvular Regurgitation Over TimeTable 2 Progressio of Aortic and/or Paravalvular Regurgitation Over Time
First Author, Year (Ref. #) n
Significant
Post-Procedural
Significant at
6 Months
Significant at
1 Year
Significant at
2 Years
Significant at
3 Years
Paravalvular leakage
Webb, 2009 (24) 168 30 days
2  37%
3  5%
— “Stable” — —
Muñoz-Garcia, 2011 (79) 144 72 h
Mild  40%
Moderate  23%
Mild  47%
Moderate  19%
— — —
Ussia, 2012 (16) 181 Post-procedure
Mild  53%
Moderate  15%
— Mild  48%
Moderate  18%
Mild  50%
Moderate  17%
Mild  47%
Moderate  10%
Ye, 2010 (80) 71 30 days
Mild  26%
Moderate  5%
— — — “Remained unchanged
and clinically
insignificant
during follow-up”
Takagi, 2011 (15) 79 30 days
1  51%
2  20%
3  3%
1  49%
2  27%
3  0%
— — —
Ewe, 2011 (81) 107 Post-procedure
1  58%
2  16%
3  5%
6 months
1  51%
2  31%
3  0%
— —
Godino, 2010 (82) 137 Post-procedure
1  60%
2  12%
3  4%
4  2%
1  65%
2  9%
3  5%
4  0%
— — —
Aortic regurgitation
Bauer, 2010 (83) 88 2  29%
3  7%
— 2  24%
3  0%
2  23%
3  0%
—
Rajani, 2010 (84) 46 Within 5 days
Mild  33%
Moderate  19%
Moderate/severe  5%
— Mild  31%
Moderate  8%
Moderate/severe  15%
— —
Clavel, 2009 (85) 50 Discharge
Trivial  38%
Mild  42%
Moderate  8%
Severe  0%
6–12 months
Trivial  26%
Mild  46%
Moderate  6%
Severe  0%
— —
Lefevre, 2011 (86) 130 Discharge
2  42%
3  5%
— 2  25%
3  0%
— —
Buellesfeld, 2011 (20) 126 30 days
1  32%
2  9%
3  0%
1  39%
2  6%
3  0%
1  34%
2  3%
3  0%
1  37%
2  0%
3  0%
—
Bleiziffer, 2012 (87) 227 Discharge
Mild  31%
Mild/moderate  13%
Moderate  8%
Moderate/severe  3%
Mild  45%
Mild/moderate  11%
Moderate  6%
Moderate/severe  0%
Severe  0%
Mild  40%
Mild/moderate  16%
Moderate  6%
Moderate/severe 0.5%
Severe  0.5%
Mild  41%
Mild/moderate  15%
Moderate  5%
Moderate/severe  1%
Severe  1%
—
Koos, 2011 (29) 57 After implant
1  77%
2  9%
3  5%
Mean 83  80 days
1  82%
2  5%
3  0%
— — —
D’Onofrio, 2011 (88) 504 Discharge
1  30%
2  9%
— Mean 9.2  6.5 months
“No changes in the
degree of AR were
found”
— —
Gurvitch, 2010 (21) 70 Post-procedure
Trivial  40%
Mild  44%
Moderate  6%
— — — Trivial  60%
Mild  33%
Moderate  3%
Walther, 2011 (22) 168 — 3–6 months
1  51%
2  1%
1  46%
2  5%
3  0%
— —3  0%
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March 19, 2013:1125–36 Paravalvular Leak After TAVRization of the valve before implantation. In addition, simul-
taneous “real-time” imaging, such as echocardiogram (both
2D and 3D), 3D angiographic reconstruction via rotational
aortic root angiogram (67), and the use of novel imaging
systems (68,69), may assist in choosing intraprocedurally the
optimal projection for THV positioning and deployment,
leading potentially to less frequent PVL.
Intraprocedurally, several interventional alternatives to
reduce regurgitation are available (70). Severe calcification
of the native valve might prevent the implanted valve from
expanding completely against the annulus, leaving residual
orifices through which PVL may occur. Post-implantation
balloon dilation of the valve might be effective in reducing
PVL and may be considered the initial option for patients
with PVL (71). A slightly oversized balloon is recom-
mended to fully expand the valve. Studies have shown that
post-dilation can be safely performed, with a reduction of
the regurgitation in a majority of patients (38). Calcification
of the valve significantly influences the success of this
intervention. However, in some patients, post-dilation has
no effect in reducing AR (15); in addition, post-dilation has
been shown to be associated with a higher incidence of
cerebrovascular events (38). The effect of post-dilation on
survival has yet to be determined.
Figure 1 Change in Paravalvular Leak Severity
Over 2-Year Follow-Up
Adapted with permission from Kodali et al. (8).
Outcomes Associated With Aortic and/or Paravalvular RegurgitatioTable 3 Outcomes Associated With Aortic and/or Paravalvular
First Author, Year (Ref. #) n Variable Outco
Abdel-Wahab, 2011 (3) 690 AR 2 In-hospital morta
Gotzmann, 2011 (4) 122 AR 2 6-month mortality
No clinical improv
Takagi, 2011 (15) 41 AR 2 6-month mortality
Hayashida, 2012 (89) 260 AR 2 Median 217 days
Leber, 2011 (90) 69 AR 2 1-year mortality
Moat, 2011 (5) 870 AR 2 1-year mortality
Sinning, 2012 (91) 152 PVL 2 1-year mortality
Tamburino, 2011 (6) 663 PVL 2 Late mortality
Sinning, 2012 (41) 146 Moderate/severe PVL 1-year survival
Unbehaun, 2012 (26) 358 No vs. trace vs. mild AR 2-year survival
Kodali, 2012 (8) 158 Mild to severe AR 2-year survival
Mild to severe PVL 2-year survivalHR  hazard ratio; IQR  interquartile range; OR  odds ratio; other abbreviations as in Table 1.Especially with the CoreValve, implantation of the valve
that is too low is associated with PVL. Repositioning to a
higher implantation depth could therefore reduce PVL.
However, no retrievable valve is currently available on the
market. Therefore, a snaring maneuver has been de-
scribed, in which the valve is pulled up by attaching a
snare to one of the frame loops (72,73). Although
successful cases have been reported (74), the valve may
also move to the original (too low) position as soon as
tension is released (70). An extra word of caution is
warranted when the snaring technique is considered in
patients with extensively calcified valves because chunks
of calcium may detach as a result of friction. Further-
more, there is a risk of damaging the ascending aorta
during the snaring maneuver.
A valve-in-valve procedure may be necessary in some
cases in which post-dilation or other techniques do not
improve the degree of PVL. This is specifically indicated for
patients in whom the valve was suboptimally positioned
(i.e., too shallow or too deep). In the Italian registry, a
valve-in-valve procedure was used in 3.6% of 663 patients
Figure 2 Impact of Paravalvular Leak
on 2-Year All-Cause Mortality
Reprinted with permission from Kodali et al. (8). HR  hazard ratio.
rgitation
Univariate Analysis Multivariate Analysis
OR  2.50 (95% CI 1.37–4.55) OR  2.43 (95% CI 1.22–4.85)
t
— OR  4.26 (95% CI 1.59–11.45)
OR  10.1 (95% CI 3.20–31.94)
12.2% vs. 25.0% (p  0.25) —
54–401) HR  1.97 (95% CI 1.19–3.28) —
9% vs. 37.5% (95% CI p  0.07) —
HR  1.49 (95% CI 1.00–2.21) HR  1.66 (95% CI 1.10–2.51)
HR  4.0 (95% CI 2.1–7.5) HR  4.9 (95% CI 2.5–9.6)
— HR  3.79 (95% CI 1.57–9.10)
HR  3.9 (95% CI 2.0–7.5) HR  2.4 (95% CI 1.0–5.4)
66% vs. 72% vs. 67% (p  0.77) —
HR  1.75 (95% CI 1.17–2.61) Not significant
HR  2.11 (95% CI 1.43–3.10) Not significantnRegu
me
lity
emen
(IQR:
T 2.5
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Paravalvular Leak After TAVR March 19, 2013:1125–36(75). Compared with patients who were implanted with a
single valve, those who underwent valve-in-valve had similar
safety and efficacy over a 1-year follow-up. Encouraging
results have been reported from other series as well (76).
As a final option for patients with continued severe PVL
in whom interventional therapy does not suffice, conversion
to conventional SAVR may be needed (77). SAVR may be
undesirable because these patients are generally at high or
extreme risk, but the procedure may be unavoidable in some
cases.
VARC II Recommendations for Evaluation of Aortic and/or ParavalvTable 4 VARC II Recommendations for Evaluation of Aortic and
Semiquantitative parameters
Diastolic flow reversal in the descending aorta—pulsed wave
Circumferential extent of prosthetic valve paravalvular regurgitation (%)*
Quantitative parameters†
Regurgitant volume (ml/beat)
Regurgitant fraction (%)
Effective regurgitant orifice area (cm2)
*Not well validated and may overestimate severity compared with quantitative Doppler. †For LVO
VARC  Valve Academic Research Consortium; other abbreviations as in Table 1.
Figure 3 Quantitative Doppler Echocardiography Can Be Used
(A) Post–transcatheter heart valve (THV) left ventricular outflow tract (LVOT) diame
(C) LVOT Doppler with sample volume located just apical to the THV stent aligned
Stroke volume (SV) across the THV  LVOT area  LVOT velocity time integral (VT
ume  LVOT SV  RVOT SV  13 ml. AR  aortic regurgitation; PG  pressure gEmerging TAVR Technologies
Currently, there is no proven or generally accepted treat-
ment for PVL. However, there are emerging THV systems
and technologies that are promising in minimizing PVL
after TAVR (Fig. 5). These devices may reduce PVL by
better supra-, infra-, or intra-annular sealing (cuff) or by
allowing controlled deployment, repositioning, or removal
of the THV. Preimplantation calcification debulking (sur-
gically or not) also remains one of the most interesting areas
Regurgitation After TAVRaravalvular Regurgitation After TAVR
Mild Moderate Severe
nt or brief early diastolic Intermediate Prominent, holodiastolic
10 10–29 30
30 30–59 60
30 30–49 50
0.10 0.10–0.29 0.30
cm, significant stenosis criteria is 0.20. Adapted with permission from Kappetein et al. (66).
lculate the Regurgitant Orifice and Volume
st apical to the THV stent). (B) Right ventricular outflow tract (RVOT) diameter.
short-axis view of the LVOT pulsed Doppler signal just below the THV stent.
6 ml. (D) RVOT VTI yields an SV across the RVOT of 43 ml. The regurgitant vol-
t.ular/or P
Abseto Ca
ter (ju
in the
I)  5
radien
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March 19, 2013:1125–36 Paravalvular Leak After TAVRof development to ensure adequate THV expansion and
annulus sealing.
Limitations of the Current Literature
Many limitations of the current literature should be ac-
knowledged. Although some studies have used echocardi-
Figure 4 3-Dimensional Echocardiography Can Be Used to Quant
(A) Multiplanar reconstruction of a 3-dimensional color Doppler volume set, aligned in
orifices are 4 mm2 and 1 mm2, consistent with a total effective regurgitant orifice are
190 ms. The regurgitant volume  EROA  AR VTI  10 ml (same patient as in Fig.
Figure 5 Emerging TAVR Devices Involving Improved Technolog
(A) SAPIEN 3 (Edwards Lifesciences, Irvine, California). (B) CENTERA (Edwards Lif
(D) Portico (St. Jude Medical, St. Paul, Minnesota). (E) Engager (Medtronic, Minne
Maple Grove, Minnesota). (G) JenaValve (JenaValve Technology, Munich, Germanyography, others have used angiography to assess PVL
immediately after THV implantation, making comparison
between studies difficult. Most of the studies have used site
self-reported PVL severity and lack independent adjudica-
tion of clinical events. Although the PARTNER trial had
the advantage of a central echocardiography core laboratory
the Regurgitant Orifice and Volume
ort-axis view of the LVOT just below the THV stent. The planimetered regurgitant
A) of 5 mm2. (B) Aortic regurgitant continuous wave spectral Doppler with AR VTI of
reviations as in Figure 3.
Potentially Minimizing PVL After TAVR
ces). (C) Direct Flow Medical (Direct Flow Medical, Santa Rosa, California).
, Minnesota). (F) Heart Leaflet Technologies (Heart Leaflet Technologies,
Sadra Lotus Medical (Boston Scientific SciMed Inc., Maple Grove, Minnesota).itate
the sh
a (ERO
3). Abbies,
escien
apolis
). (H)
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in-depth analysis of the outcomes associated with PVL.
Baseline characteristics of patients with no/trace PVL may
be different than those with mild to severe PVL and may
explain the difference in mortality and the absence of PVL
as a predictor for mortality in several reported multivariable
analyses. Finally, better criteria to establish PVL severity are
needed to ensure appropriate classification and uniformity
among studies.
Conclusions
The association of PVL after TAVR with mortality has
made it the new “in vogue” Achilles’ heel of TAVR.
Although post-procedural moderate to severe PVL can
understandably be a predictor of a worse outcome, the
association with mild PVL may be debatable. Given the
limitations of the current literature, the nature and strength
of the relationship between PVL and mortality are still to be
determined. Future studies should standardize the evalua-
tion of PVL and ensure an appropriate classification of its
severity. Upcoming THV systems should be designed to
minimize PVL, and emerging technology, such as nonin-
vasive calcification debulking of the aortic valvular complex,
brings promises of lower PVL rates after TAVR, potentially
as low as those after SAVR.
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